How we treat patients with leptomeningeal metastases
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The goal of treatment of leptomeningeal metastasis is to improve survival and to maintain quality of life by delaying neurological deterioration. Tumour-specific therapeutic options include intrathecal pharmacotherapy, systemic pharmacotherapy and focal radiotherapy. Recently, improvement of leptomeningeal disease-related progression-free survival by adding intrathecal liposomal cytarabine to systemic treatment versus systemic treatment alone has been observed in a randomised phase III trial for patients with breast cancer with newly diagnosed leptomeningeal metastasis. Safety and efficacy of intrathecal administration of new agents such as trastuzumab are under evaluation. Systemic therapy using targeted agents and immunotherapy has also improved outcome in patients with brain metastasis, and its emerging role in the management of leptomeningeal metastasis needs to better studied in prospective series. Focal radiotherapy is commonly indicated for the treatment of macroscopic disease such as meningeal nodules or clinically symptomatic central nervous system structures, for example, base of skull with cranial nerve involvement or cauda equine syndrome. The role of whole brain radiotherapy is decreasing. An individualised combination of different therapeutic options should be used considering the presentation of leptomeningeal metastasis, as well as the histological and molecular tumour characteristics, the presence of concomitant brain and systemic metastases, and prior cancer-directed treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, two prospective trials have shown that the addition of intrathecal to systemic therapy has no OS or QoL advantage.102”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [102]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Their use can cause a spectrum of toxicities ranging from myelosuppression to neurotoxicity.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [102]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three agents are commonly used for intrathecal treatment of LMD: methotrexate, cytarabine (including liposomal cytarabine) or thioTEPA.100, 101, 102”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [102]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Retrospective data suggest some activity of different agents used systemically.100, 101, 102”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [102]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637 · cited 5×
“In the presence of cranial nerve impairment, irradiation of skull base, interpeduncular cistern or the two first cervical vertebrae may be indicated; irradiation of lumbosacral vertebrae may be indicated for cauda equina syndrome.(1) No survival benefit of WBRT was observed in most retrospective studies of patients wi…”
BackgroundMethodInfluentialSelf-citationGlantz, M., Jaeckle, K. A., Chamberlain, M. C., Phuphanich, S., Recht, L. D., Swinnen, L. J., Maria, B., LaFollette, S., Schumann, G. B., Cole, B. F., et al. (1999) · PubMed · Cited by 529
Grossman, S. A., Finkelstein, D. M., Ruckdeschel, J. C., Trump, D. L., Moynihan, T., & Ettinger, D. S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.561 · Cited by 364
Hitchins, R. N., Bell, D. R., Woods, R. L., & Levi, J. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1655 · Cited by 352
Boogerd, W., van den Bent, M. J., Koehler, P. J., Heimans, J. J., van der Sande, J. J., Aaronson, N. K., Hart, A. A. M., Benraadt, J., & Vecht, C. J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.08.012 · Cited by 286 · cited 1×
“57 months in the combined modality arm).(6) Yet, enrolment was stopped after 35 instead of 50 patients because of poor accrual, and a high rate of ventricular infection was noted with 18% of reservoir revisions which may have negatively influenced outcome in the experimental arm.”
BackgroundRhun, É. L., Devos, P., Boulanger, T., Smits, M., Brandsma, D., Rudà, R., Furtner, J., Hempel, J.-M., Postma, T. J., Roth, P., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz024 · Cited by 142
Self-citationPan, Z., Yang, G., He, H., Zhao, G., Yuan, T., Li, Y., Shi, W., Gao, P., Dong, L., & Li, Y. (2016) · International Journal of Cancer · doi:10.1002/ijc.30214 · Cited by 116
Glantz, M., Horn, A. V., Fisher, R., & Chamberlain, M. C. (2010) · Cancer · doi:10.1002/cncr.24921 · Cited by 113 · cited 1×
“1136/esmoopen-2019-000507 presumably due to the different half-lives of the agents.(10) Altogether, clinical experience and available evidence favour the intraventricular route.”
BackgroundYang, J. C., Kim, D., Kim, S., Cho, B. C., Lee, J.-S., Ye, X., Yin, X., Yang, Z., Jiang, H., & Ahn, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9002 · Cited by 95
Bonneau, C., Paintaud, G., Trédan, O., Dubot, C., Desvignes, C., Dieras, V. C., Taillibert, S., Tresca, P., Turbiez, I., Li, J., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.032 · Cited by 94 · cited 1×
“Trastuzumab has been evaluated in a phase I study in patients with breast cancer with leptomeningeal metastases with Her2-positive tumours, with a good tolerance (NCT01373710).(9) Data of a second trial on safety of dose-escalated intrathecal trastuzumab are still pending (NCT01325207).”
Background
Cited by
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
“] and taking into account the patient’s life expectancy.(102) Available active treatment options are RT, intra-CSF therapy and systemic therapy.”
BackgroundMethodInfluentialTolaney, S. M., Sahebjam, S., Le Rhun, E., Bachelot, T., Kabos, P., Awada, A., Yardley, D., Chan, A., Conte, P., Diéras, V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1764 · Cited by 203
Aizer, A. A., Lamba, N., Ahluwalia, M. S., Aldape, K., Boire, A., Brastianos, P. K., Brown, P. D., Camidge, D. R., Chiang, V. L., Davies, M. A., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac118 · Cited by 202
Self-citationLeptomeningeal Metastasis from Non–Small Cell Lung Cancer and Current Landscape of Treatments
Ozcan, G., Singh, M., & Vredenburgh, J. J. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1585 · Cited by 136
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
Brastianos, P. K., Strickland, M. R., Lee, E. Q., Wang, N., Cohen, J. V., Chukwueke, U. N., Forst, D. A., Eichler, A. F., Overmoyer, B. A., Lin, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25859-y · Cited by 92
Metadata
- Authors
- Le Rhun, E., Preusser, M., van den Bent, M., Andratschke, N., & Weller, M.
- Affiliations
- Medical University of Vienna (AT)
- University of Zurich (CH)
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2019
- Volume
- 4
- Issue
- Suppl 2
- Pages
- e000507
- ISSN
- 2059-7029 (ISSN-L)
- PMC
- PMC6555600
- OpenAlex
- W2946608588
- Cited by
- 127
- References
- 18
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 19 · 2023: 31 · 2022: 17 · 2021: 15 · 2020: 15 · 2019: 5
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 728 d)
- Locations
- ESMO Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- leptomeningeal metastasis, intrathecal chemotherapy, liposomal cytarabine, systemic chemotherapy, focal radiotherapy, cauda equina syndrome, whole brain radiotherapy, breast cancer, trastuzumab, targeted therapy, immunotherapy, progression-free survival, quality of life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How we treat patients with leptomeningeal metastases. https://app.cochat.ai/papers/10.1136/esmoopen-2019-000507
- The paper
- Le Rhun, E., Preusser, M., van den Bent, M., Andratschke, N., & Weller, M. (2019). How we treat patients with leptomeningeal metastases. ESMO Open. https://doi.org/10.1136/esmoopen-2019-000507
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
